Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On September 17, 2025, we reported on results from the US-based INFORM survey presented at the European Association for the Study of Diabetes (EASD) 2025, September 15-19, in Vienna, Austria.
The survey
Investigators used a previously validated Food Noise Questionnaire with 22 questions to assess the impact of semaglutide (Wegovy, Novo Nordisk) on mental well-being and eating habits relating to food noise among 550 participants. The survey population had a mean age of 53 years and the majority (86%) were women. Approximately two-thirds (64%) reported weighing 92 kg (~203 lbs) or more when they began semaglutide treatment.
The findings
The number of people who reported experiencing constant thoughts about food throughout the day declined by 46% after starting treatment with semaglutide. Before starting semaglutide treatment, 62% of participants reported constant food-related thoughts, compared with only 16% while taking the injectable incretin mimetic. The negative impact of food noise on daily life also improved, with just 20% of participants reporting disruption while taking semaglutide, compared with 60% who reported the impact before treatment.
As food noise became less intrusive, survey responses revealed substantial improvements in overall well-being. Approximately 64% of respondents reported improved mental health since starting semaglutide treatment, while 76% developed a "healthier lifestyle" and 80% developed "healthier habits." The majority of study participants (83%) reported high satisfaction with semaglutide treatment.
